417 related articles for article (PubMed ID: 36982415)
1. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
2.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
3. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma.
Yin X; Wang Z; Wang J; Xu Y; Kong W; Zhang J
Oncoimmunology; 2021; 10(1):1933332. PubMed ID: 34262797
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
6. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
7. A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma.
Peng L; Liang J; Wang Q; Chen G
Front Genet; 2022; 13():798846. PubMed ID: 35656315
[No Abstract] [Full Text] [Related]
8. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
9. Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Jun; 36(6):e24409. PubMed ID: 35441741
[TBL] [Abstract][Full Text] [Related]
10. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
11. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
[TBL] [Abstract][Full Text] [Related]
12. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
13. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
14. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
Tai R; Leng J; Li W; Wu Y; Yang J
BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a Seven-Gene Signature Associated with CD8
Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
[TBL] [Abstract][Full Text] [Related]
16. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
Front Immunol; 2022; 13():971142. PubMed ID: 36131921
[TBL] [Abstract][Full Text] [Related]
17. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
18. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.
Wu X; Xie W; Gong B; Fu B; Chen W; Zhou L; Luo L
Front Oncol; 2023; 13():1162846. PubMed ID: 38023248
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of m
Wu J; Hou C; Wang Y; Wang Z; Li P; Wang Z
Int J Genomics; 2021; 2021():3803724. PubMed ID: 34631874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]